Prophylactic Drug Delivery System for COVID-19

Heather Sheardown | Via McMaster University | May 22, 2020

The Heather Sheardown lab (McMaster University, Canada) is home to an interdisciplinary team of scientists and trainees with expertise in ophthalmology, polymer and biomaterial engineering, chemistry, pharmaceutical formulation and drug delivery, animal/ex-vivo/in-vitro models of disease and drug delivery, early stage material design and synthesis, and synthetic method scalability optimization.

As the availability of a SARS-CoV-2 vaccine is still far off, there is an immediate global need for prophylactic prevention strategies, particularly for vulnerable populations including seniors and frontline workers. The Sheardown lab has developed a mucoadhesive polymeric micelle that allows for the encapsulation of a range of therapeutics, providing local, controlled delivery to mucosal surfaces. This technology overcomes traditional solubility concerns, allowing formulations at higher drug concentrations. Its mucosal binding significantly reduces dosing frequency, increases local bioavailability and improves clinical efficacy. Developed and validated for safety and efficacy in the eye, this system is now being repurposed for the mucosa of the respiratory tract, formulated as a nasal spray or inhaled aerosol, incorporating two treatments that are currently under study internationally: hydroxychloroquine (HCQ) and remdisivir… Continue reading.